ANRO — Alto Neuroscience Cashflow Statement
0.000.00%
Last trade - 00:00- $164.63m
- $39.16m
- 33
- 33
- 29
- 21
Annual cashflow statement for Alto Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -9.19 | -27.7 | -36.3 | -61.4 |
| Depreciation | ||||
| Non-Cash Items | 0.352 | 2.4 | 3.18 | 9.45 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -0.572 | 4.58 | -0.698 | 4.06 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -9.26 | -20.4 | -33.4 | -47.4 |
| Capital Expenditures | -0.68 | -0.732 | -0.47 | -2.08 |
| Purchase of Fixed Assets | ||||
| Cash from Investing Activities | -0.68 | -0.732 | -0.47 | -2.08 |
| Financing Cash Flow Items | -0.205 | -0.341 | -2.05 | -3.33 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 31.7 | 43.8 | 68.1 | 136 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 21.7 | 22.6 | 34.2 | 86.2 |